Sleep disorders in patients with dementia in Parkinson's disease

Litvinenko I.V.; Krasakov I.V.; Tikhomirova O.V.

doi:https://doi.org/

Close metadata

Recommended articles:

Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22

Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):23-27

Experience of using the combined drug Mioreol in patients with Alzheimer’s disease and mixed dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):34-43

Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):51-59

Association of inflammation and chronic fatigue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87

Electric activity of the brain at early and late clinical stages of experimental modeling of Parkinson’s disease, an impact of hemantane. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):129-134

Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34

The possibilities of Mexidol in the complex therapy of arterial hypertension. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):572-580

International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;(10):72-83

Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;(11):85-93

Abstract:

Dementia and psychotic disorders are frequent complications of Parkinson's disease (PD). They occurred in 40-60% of the cases. These complications are often accompanied by sleep disorders which also are non-motor presentations of PD. The objectives of the present study were 1) the assessment of correlations of daily sleepiness and behavioral disturbances during the fast sleep phase (REM-phase) with cognitive impairment and hallucinations; 2) the comparison of evaluation of sleep disorders in PD with questionnaires or polysomnographic study; 3) the assessment of the effect of galantamine on sleep disorders. Using a battery of scales (MMSE, FAB, ESS, PDSS) and polysomnographic study, we evaluated a state of sleep and cognitive functions in 26 PD patients with dementia before and after treatment with galantamine. The results obtained demonstrated the significant negative correlations of the severity of sleep disorders (excessive day sleepiness and disturbances of behavior in REM-phase) with hallucinations and cognitive disorders. Galantamine improved the quality of night sleep (the restoration of structure, decrease of fragmentation), decreased the severity of behavior disorders during REM-phase and day sleepiness along with changes in the intensity of cognitive disturbances and hallucinations.

Keywords:

Parkinson's disease

dementia

sleep disorders

cognitive disturbances

galantamine

Authors:

Litvinenko I.V.

Kafedra nervnykh bolezneĭ i kafedra psikhiatrii Voenno-meditsinskoĭ akademii

SPIN RSCI: 6112-2792
Scopus AuthorID: 35734354000
ResearcherID: F-9120-2013
ORCID: 0000-0001-8988-3011

Krasakov I.V.

Tikhomirova O.V.

Close metadata

References:

Litvinenko I.V., Sakharovskaya A.A., Leonova E.V. Atomoksetin polozhitel'no vliyaet na vnimanie, khod'bu i dnevnuyu sonlivost' u patsientov na pozdnikh stadiyakh bolezni Parkinsona. Materialy Vserossiiskoi yubileinoi nauchno-prakticheskoi konferentsii "Aktual'nye problemy klinicheskoi nevrologii". St-Peterburg 2009; 32.
Litvinenko I.V., Odinak M.M., Mogil'naya V.I., Emelin A.Yu. Effektivnost' i bezopasnost' primeneniya galantamina (reminila) v sluchayakh dementsii pri bolezni Parkinsona. Zhurn nevrol i psikhiat 2010; 110: 12: 21-29.
Nodel' M.R., Yakhno N.N. Mirapeks (pramipeksol) v lechenii nedvigatel'nykh narushenii pri bolezni Parkinsona. Zhurn nevrol i psikhiat 2008; 108: 5: 32-38.
Nodel' M.R. Vliyanie terapii agonistom dofaminovykh retseptorov mirapeksom (pramipeksol) na narusheniya sna pri bolezni Parkinsona. Zhurn nevrol i psikhiat 2010; 110: 3: 42-47.
Albin R.L., Koeppe R.A., Chervin R.D. et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000; 55: 1410-1412.
American Academy of Sleep Medicine. International classification of sleep disorders 2nd ed.: Diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine 2005.
Anderson K.N., Jamieson S., Graham A.J., Shneerson J.M. REM sleep behavior disorder treated with melatonin in a patient with Alzheimer's disease. Clin Neurol Neurosurg 2008; 110: 492-495.
Anderson K.N., Shneerson J.M. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009; 5: 235-239.
Aurora R.N., Zak R.S., Maganti R.K. et al. Standards of Practice Committee; American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). Journal of Clinical Sleep Medicine 2010; 6: 1.
Baumann C. Parkinsonism with excessive daytime sleepiness - a narcolepsy-like disorder? J Neurol 2005; 252: 2: 139-145.
Boeve B.F., Silber M.H., Ferman T.J. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4: 281-284.
Boeve B.F., Silber M.H., Saper C.B. et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770-2788.
Chauduri K.R., Schapira A.H.V. Non-motor symptoms of Parkinsons disease: dopaminergic patophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
Comella C. Sleep disorders in Parkinson's disease: an overview. Mov Disord 2007; 22: Suppl 17: 367-373.
Compta Y., Santamaria J., Ratti L. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009; 132: Pt 12: 3308-3317.
Day J., Damsma G., Fibiger H.C. Cholinergic activity in the rat hippocampus, cortex and striatum correlates with locomotor activity: an in vivo microdialysis study. Pharmacol Biochem Behav 1991; 38: 723-729.
Eisensehr I., Linke R., Noachtar S. et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder: comparison with Parkinson's disease and controls. Brain 2000; 123: 1155-1160.
Friedman J.H., Millman R.P. Sleep Disturbances and Parkinson's Disease. CNS Spectr 2008; 13: 3: Suppl 4: 12-17.
Grace J.B., Walker M.P., McKeith I. A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000; 15: 1028-1033.
Hickey M.G., Demaerschalk B.M., Caselli R.J. et al. "Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases. Neurologist 2007; 13: 2: 98-101.
Hobson D. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 4: 455-463.
Iranzo A., Molinuevo J.L., Santamaria J. et al. Rapid-eye movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572-577.
Kunz D., Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999; 14: 507-511.
Lapierre O., Montplaisir J. Polysomnographic features of REM sleep behavior disorder: Development of a scoring method. Neurology 1992; 42: 1371-1374.
Litvinenko I., Ognev D., Sakharovskaya A. Atomoxetine improves sleepiness, attention and gait in advanced Parkinson's disease. 13th Congress of the European Federation of Neurological Societies: abstracts. Florence: European Journal of Neurology 2009; 16: Suppl 3: 2600.
Maclean L.E., Collins C.C., Byrne E.J. Dementia with Lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriat 2001; 13: 277-288.
Mahowald M.W., Schenck C.H. REM sleep parasomnias. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine 4th ed. Philadelphia: Elsevier Saunders 2005; 897-916.
Marion M.H., Qurashi M., Marshall G., Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease? J Neurol 2008; 255: 2: 192-196.
Massironi G., Galluzzi S., Frisoni G.B. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr 2003; 15: 377-383.
Moraes W.A., Poyares D.R., Guilleminault C. et al. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: A double-blind placebo-controlled study. Sleep 2006; 29: 199-205.
Morrison A.R., Mann G.L., Hendricks J.C. The relationship of excessive exploratory behavior in wakefulness to paradoxical sleep without atonia. Sleep 1981; 4: 247-257.
Niederhofer H. Donepezil in the treatment of narcolepsy. J Clin Sleep Med 2006; 15: 2: 1: 71-72.
Olson E.J., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331-339.
Parish J.M. Violent dreaming and antidepressant drugs: or how paroxetine made me dream that I was fighting Saddam Hussein. J Clin Sleep Med 2007; 3: 529-531.
Postuma R.B., Gagnon J.F., Vendette M. et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 15: 1296-1300.
Rye D.B. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 1997; 20: 757-788.
Schenck C.H., Bundlie S.R., Ettinger M.G., Mahowald M.W. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9: 293-308.
Schenck C.H., Mahowald M.W. A polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89,5% of 57 treated patients. Clev Clin J Med 1990; 57: Suppl: 9-23.
Schenck C.H., Mahowald M.W., Kim S.W. et al. Prominent eye movements during nrem sleep and rem sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992; 15: 226-235.
Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996; 46: 388-393.
Schenck C.H., Mahowald M.W. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996; 100: 333-337.
Schenck C.H., Bundlie S.R., Mahowald M.W. REM Behavior Disorder (RBD): Delayed emergence of Parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum and maximum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003; 26: Abstract supplement: 316.
Schuld A., Kraus T., Haack M. et al. Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder. J Sleep Res 1999; 8: 4: 321-322.
Schutte S., Doghramji K. REM behavior disorder seen with Venlafaxine (Effexor). Sleep Res 1996; 25: 364.
Takeuchi N., Uchimura N., Hashizume Y. et al. Melatonin therapy for REM sleep behavior disorder. Psychiat Clin Neurosci 2001; 55: 267-269.
Uchiyama M., Isse K., Tanaka K. et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 1995; 45: 709-712.
Vendette M., Gagnon J.F., Décary A. et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007; 6: 69: 19: 1843-1849.
Weintraub D., Mavandadi S., Mamikonyan E. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 3: 75: 5: 448-455.
Wing Y.K., Lam S.P., Li S.X. et al. REM sleep behaviour disorder in Hong Kong Chinese: clinical outcome and gender comparison. J Neurol Neurosurg Psychiatry 2008; 79: 12: 1415-1416.
Winkelman J.W., James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004; 27: 317-321.
Zahodne L., Fernandez H. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008; 25: 8: 665-682.